A phase II study of gemcitabine at fixed infusion rate of 10 mg/m(2)/min with or without immunotherapy in advanced renal cancer

作者：Zustovich Fable^*; Cartei Giuseppe; Pastorelli Davide; Nicoletto Ornella; Gottardo Fedra; De Zorzi Luca; Dal Bianco Massimo

来源：Anticancer Research, 2007, 27(6C): 4461-4464.

• kidney cancer
• gemcitabine
• immunotherapy

Background: Advanced renal cancer remains a challenge for oncologists since no treatment other than surgery has demonstrated a clear survival advantage. Patients and Methods: Gemcitabine was given to suitable patients at a fixed infusion rate of 10 mg/m(2)/min. Eighteen patients received concomitant immunotherapy, mostly low doses of interleukin 2 (IL2). Results: Thirty patients were enrolled. The overall response rate was 14% (22% in the subset of patients treated with both chemotherapy and immunotherapy) with a median progression-free survival time of 4.1 + months. Toxicity was not mild, mostly fatigue, nausea and anaemia, even though not life threatening. Conclusion: Gemcitabine at the fixed infusion rate of 10 mg/m(2)/min with concomitant low doses of IL2 could be useful in the palliative treatment of symptomatic patients with renal carcinoma progressing after tyrosine kinases inhibitor.

• 出版日期2007-12